Literature DB >> 22461033

Central nervous system lesions due to juvenile myelomonocytic leukemia progressed in a boy undergoing first line chemotherapy.

Hiroko Fukushima1, Takashi Fukushima, Akiyoshi Hiraki, Ryoko Suzuki, Shaza S A Mahmoud, Ai Yoshimi, Tomohei Nakao, Keisuke Kato, Chie Kobayashi, Kazutoshi Koike, Masakatsu Fukasawa, Yukio Morishita, Sayoko Doisaki, Hideki Muramatsu, Ryo Sumazaki.   

Abstract

Juvenile myelomonocytic leukemia is a rare malignancy that occurs in pediatric patients. Previous reports, have described leukemic cells may infiltrate many organs, such as the lungs, skin, liver, spleen, and intestines, but not the central nervous system, although central nervous system infiltration remains a point of concern in every patient with acute leukemia. Here, we present one case of a boy with juvenile myelomonocytic leukemia who developed multiple lesions in the brain while undergoing chemotherapy with 6-mercaptopurine and cytarabine. We diagnosed the central nervous system involvement by magnetic resonance imaging, cerebrospinal fluid cytology, and the patient's clinical course. He was treated with a high dose of cytarabine and intrathecal chemotherapy, then with unrelated cord blood stem cell transplantation. He has been in a first complete remission for more than 18 months after cord blood stem cell transplantation without any neurological sequelae. In conclusion, we encountered a boy with juvenile myelomonocytic leukemia who developed central nervous system lesions under standard chemotherapy. We subsequently switched treatment to central nervous system-oriented chemotherapy, which resulted in a good clinical condition and successful cord blood stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22461033     DOI: 10.1007/s12185-012-1046-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  6 in total

1.  Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.

Authors:  Kazuyuki Matsuda; Akira Shimada; Nao Yoshida; Atsushi Ogawa; Akihiro Watanabe; Shuhei Yajima; Susumu Iizuka; Kazutoshi Koike; Fumio Yanai; Keiichiro Kawasaki; Masakatsu Yanagimachi; Akira Kikuchi; Yoshitoshi Ohtsuka; Eiko Hidaka; Kazuyoshi Yamauchi; Miyuki Tanaka; Ryu Yanagisawa; Yozo Nakazawa; Masaaki Shiohara; Atsushi Manabe; Seiji Kojima; Kenichi Koike
Journal:  Blood       Date:  2007-03-01       Impact factor: 22.113

Review 2.  Juvenile myelomonocytic leukemia presenting with facial nerve paresis: a unique presentation.

Authors:  Lorie B Smith; Yamily Valdes; William E Check; Peter M Britt; Lawrence S Frankel
Journal:  J Pediatr Hematol Oncol       Date:  2007-11       Impact factor: 1.289

3.  Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial.

Authors:  Franco Locatelli; Peter Nöllke; Marco Zecca; Elisabeth Korthof; Edoardo Lanino; Christina Peters; Andrea Pession; Hartmut Kabisch; Cornelio Uderzo; Carmen S Bonfim; Peter Bader; Dagmar Dilloo; Jan Stary; Alexandra Fischer; Tom Révész; Monika Führer; Henrik Hasle; Monika Trebo; Marry M van den Heuvel-Eibrink; Susanna Fenu; Brigitte Strahm; Giovanna Giorgiani; Mario Regazzi Bonora; Ulrich Duffner; Charlotte M Niemeyer
Journal:  Blood       Date:  2004-09-07       Impact factor: 22.113

Review 4.  Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.

Authors:  Kenichi Koike; Kazuyuki Matsuda
Journal:  Br J Haematol       Date:  2008-04-13       Impact factor: 6.998

5.  Isolated CNS relapse following stem cell transplantation for juvenile myelomonocytic leukemia.

Authors:  David B Wilson; Jeff M Michalski; William J Grossman; Robert J Hayashi
Journal:  J Pediatr Hematol Oncol       Date:  2003-11       Impact factor: 1.289

6.  A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.

Authors:  Miharu Yabe; Masahiro Sako; Hiromasa Yabe; Yuko Osugi; Hidemitsu Kurosawa; Taemi Nara; Mika Tokuyama; Souichi Adachi; Chie Kobayashi; Masakatsu Yanagimachi; Yoshitoshi Ohtsuka; Yozo Nakazawa; Chitose Ogawa; Atsushi Manabe; Seiji Kojima; Tatsutoshi Nakahata
Journal:  Pediatr Transplant       Date:  2008-04-06
  6 in total
  1 in total

1.  Facial Diplegia as Initial Manifestation of Acute, Myelomonocytic Leukemia with Isolated Trisomy 47, XY,+11[14]/46, XY[6].

Authors:  Josef Finsterer; Michael Panny
Journal:  J Neurosci Rural Pract       Date:  2017 Jul-Sep
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.